Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction (DIASTOLE)
This study is currently recruiting participants.
Verified April 2012 by UMC Utrecht
Sponsor:
UMC Utrecht
Collaborator:
VU University of Amsterdam
Information provided by (Responsible Party):
Michiel Voskuil, MD, PhD, UMC Utrecht
ClinicalTrials.gov Identifier:
NCT01583881
First received: April 19, 2012
Last updated: April 23, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Increasing evidence suggests an important role of activation of the sympathetic nervous system (SNS) in the clinical phenomena of heart failure with normal left ventricular ejection fraction and hypertension. The current study aims to evaluate efficacy and safety of renal sympathetic denervation for the modulation of the SNS in patients with heart failure with normal LV ejection fraction.
| Condition | Intervention | Phase |
|---|---|---|
|
Diastolic Heart Failure Hypertension |
Procedure: renal denervation |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction |
Resource links provided by NLM:
Further study details as provided by UMC Utrecht:
Primary Outcome Measures:
- Change from baseline E/E' at 12 months [ Time Frame: 12 months after treatment ] [ Designated as safety issue: No ]Echocardiography will be used to measure the E/E'
Secondary Outcome Measures:
- Number of participants with adverse events [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 60 |
| Study Start Date: | April 2012 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Renal denervation
Renal denervation
|
Procedure: renal denervation
Renal denervation
|
| No Intervention: control |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Individual is diagnosed with heart failure with a normal LV ejection fraction. The diagnosis of HFNEF requires the following conditions to be satisfied:
- signs or symptoms of heart failure;
- normal or mildly abnormal systolic LV function (LVEF ≥ 50%);
- evidence of diastolic LV dysfunction.
- Individual should fulfill the diagnostic WHO criteria for hypertension: SBP > 140 mmHg and/or DBP > 90 mmHg, and is treated with at least 2 antihypertensive drugs. This treatment is expected to be maintained for at least 6 months. Using this regimen the blood pressure should be adequately controlled (< 140/90mmHg by 24 hour ambulatory BP measurement).
- Individual is adhering to a stable drug regimen HFNEF, with no changes for a minimum of 2 weeks prior to enrollment, and which is expected to be maintained for at least 6 months.
- Individual is ≥ 18 years of age.
Exclusion Criteria:
- Known secondary cause of hypertension
- Anatomy not eligible for renal denervation
- Systolic heart failure (LVEF < 50%)
- Individual has an estimated glomerular filtration rate (eGFR) of < 30mL/min/1.73m2, using the MDRD calculation.
- Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia, significant anaemia, or arrhythmias such as atrial fibrillation).
- Individual is pregnant, nursing or planning to be pregnant.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01583881
Contacts
| Contact: Willemien Verloop, MD | 0031887559447 | w.l.verloop@umcutrecht.nl |
| Contact: Michiel Voskuil, MD, PhD |
Locations
| Netherlands | |
| VUmc | Recruiting |
| Amsterdam, Netherlands | |
| Contact: Cor Allaart, MD, PhD cp.allaart@vumc.nl | |
| UMC Utrecht | Recruiting |
| Utrecht, Netherlands | |
| Contact: Willemien Verloop, MD w.l.verloop@umcutrecht.nl | |
| Contact: Voskuil, MD, PhD m.voskuil@umcutrecht.nl | |
Sponsors and Collaborators
UMC Utrecht
VU University of Amsterdam
Investigators
| Principal Investigator: | Michiel Voskuil, MD, PhD | UMC Utrecht |
More Information
No publications provided
| Responsible Party: | Michiel Voskuil, MD, PhD, MD. PhD., UMC Utrecht |
| ClinicalTrials.gov Identifier: | NCT01583881 History of Changes |
| Other Study ID Numbers: | 12-046 |
| Study First Received: | April 19, 2012 |
| Last Updated: | April 23, 2012 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
Keywords provided by UMC Utrecht:
|
Patients with diastolic heart failure and hypertension |
Additional relevant MeSH terms:
|
Heart Failure Hypertension Heart Failure, Diastolic |
Heart Diseases Cardiovascular Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 23, 2013